Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

ID Number 14-1569

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to look at what happens (both good and bad) when daratumumab (the experimental medication used in this study which is also known as JNJ-54767414) is given with two other drugs called lenalidomide and dexamethasone compared to just giving those two drugs, lenalidomide and dexamethasone alone.  Giving lenalidomide and dexamethasone together is standard treatment for advanced multiple myeloma and is already approved to be used in many countries.  The safety of daratumumab when given with lenalidomide and dexamethasone will also be studied.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: No